Last reviewed · How we verify
NCT06123468
Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma
Phase 1, PHASE2 trial testing Sacituzumab govitecan in Esophagogastric Adenocarcinoma in 58 participants. Completed in 7 January 2026.
7 January 2026
Quick facts
| Lead sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 58 |
| Start date | 17 April 2024 |
| Primary completion | 7 January 2026 |
| Estimated completion | 7 January 2026 |
| Sites | 8 locations across Austria, Germany |
Drugs / interventions tested
- Sacituzumab govitecan — full drug profile →
Conditions studied
- Esophagogastric Adenocarcinoma — all drugs for Esophagogastric Adenocarcinoma →
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — full company profile →
Who can join
18 and older, any sex, with Esophagogastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors.
Tolaney SM, Cardillo TM, Chou CC, Dornan C, et al · · 2025 · cited 19× · PMID 39903492 · DOI 10.1158/1078-0432.ccr-24-1525 -
SAGA-a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma.
Kobitzsch B, Stocker G, Hacker UT, Junge S, et al · · 2024 · cited 1× · PMID 41648033 · DOI 10.1016/j.esmogo.2024.100051 -
Noninvasive Evaluation of Trop2 Expression Using <sup>64</sup>Cu-NOTA-Trodelvy-F(ab')<sub>2</sub> in Gastric and Pancreatic Cancer.
Huang W, Chao F, Li R, Yang Y, et al · · 2025 · cited 1× · PMID 41201395 · DOI 10.1021/acs.molpharmaceut.5c01223 -
Expanding the potential of antibody-drug conjugates in gastrointestinal malignancies: beyond HER2 targets.
Ntellas P, Athauda A, Sugiyama K, Le ML, et al · · 2025 · PMID 41646266 · DOI 10.1016/j.esmogo.2025.100154
Verify or expand the search:
- PubMed search for NCT06123468
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sacituzumab govitecan
Trials testing the same drug.
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07461454 — YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
- NCT07178730 — NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple- · Phase 3 · not yet recruiting
- NCT07011654 — Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) · Phase 1, PHASE2 · recruiting
- NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously · Phase 3 · recruiting
Other recruiting trials for Esophagogastric Adenocarcinoma
Currently open trials in the same condition.
- NCT06731803 — Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Re · Phase 1, PHASE2 · recruiting
- NCT06623396 — A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer · Phase 1 · recruiting
Other Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trials
Trials by the same sponsor.
- NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
- NCT07365930 — NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy · recruiting
- NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
- NCT06731803 — Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Re · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06123468 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06123468.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing